Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
28 hedge funds and large institutions have $33.1M invested in Astria Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 6 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
216% more capital invested
Capital invested by funds: $10.5M → $33.1M (+$22.6M)
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
22% more funds holding
Funds holding: 23 → 28 (+5)
15.49% more ownership
Funds ownership: 20.86% → 36.35% (+15%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$6.48M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$838K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$624K |
| 4 |
Renaissance Technologies
New York
|
+$500K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$355K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$182K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$147K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$50K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12K |
ATXS Hedge Fund Activity: Q1 2019 in Review
28 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2019, worth a combined $33.1M — up 216% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATXS positions and 6 closed out — a net gain of 5 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Federated Hermes, adding an estimated $6.48M. The largest seller was Deutsche Bank, cutting an estimated $355K.
- 28 institutional investors held Astria Therapeutics (ATXS) as of Q1 2019, up from 23 in Q4 2018.
- Funds reported $33.1M of Astria Therapeutics stock for Q1 2019, up 216% quarter-over-quarter.
- 11 funds opened new Astria Therapeutics positions in Q1 2019 and 6 closed out, a net change of +5 holders.
- The largest Astria Therapeutics buyer in Q1 2019 was Federated Hermes, an estimated $6.48M added.
- The largest Astria Therapeutics seller in Q1 2019 was Deutsche Bank, an estimated $355K sold.
Based on aggregated 13F filings for Q1 2019.